Abstract Survival rates for ovarian cancer have remained relatively stable for the past 2 decades despite advances in surgical techniques and cytotoxic chemotherapeutics, indicating a requirement for better therapies. One pathway currently proposed for targeting is the HGF/cMET pathway. Upregulated in a number of tumour types, cMET is a tyrosine kinase receptor expressed on epithelial cells. In ovarian cancer, it has been identified as highly expressed in the four major subtypes, with expression estimates ranging from 11 to 68 % of cases. HGF, the only known ligand for cMET, is found at high levels in both serum and ascites in women with ovarian cancer, and is proposed to induce both migration and metastasis. However, clinically validated biomarkers are not yet available for either HGF or cMET, preventing a clear understanding of the true rate of overexpression, or its correlation with prognosis. Despite this, a number of agents against HGF and cMET are currently being investigated in clinical trials for multiple tumour types, including ovarian. However, a lack of patient selection, biomarker usage, and post hoc analysis correlating response with expression has resulted in the majority of these trials showing little beneficial effect from these agents, indicating that additional research is required to determine their usefulness in patients with ovarian cancer.
Introduction
Ovarian cancer is the deadliest of the gynaecological malignancies, and is the fifth most common cause of cancer-related deaths in women [1] . Survival rates for epithelial ovarian cancer (EOC), which accounts for 90 % of ovarian cancer diagnoses, have remained relatively stable for the past 2 decades, despite advances in surgical options and chemotherapeutics.
Classification of Epithelial Ovarian Cancer (EOC)
In recent years, EOC has been classified as being of type I or II, with the former being described as being indolent and, on a molecular trajectory, from benign to atypical proliferative through to invasive tumours. These type I lesions typically remain within the ovary, and are classified as genomically stable, without TP53 mutations, and comprise the low-grade serous-papillary, endometrioid, clear cell, mucinous, tumours, and borderline tumours of low malignant potential [2] . On the other hand, type II EOCs are thought to be de novo aggressive, and are frequently diagnosed when metastases are already present. They are genetically unstable and universally contain TP53 mutations and dysfunctional breast cancer genes, BRCA1/2 (which results in further chromosomal disruption). Their origin has long been debated but current evidence points to the secretory epithelium of the distal fallopian tube (reviewed by Kurman et al. [2, 3] ). High-grade serous carcinomas, high-grade endometrioid, and undifferentiated carcinomas [2] are classified as type II EOCs. Overall survival rates for the two types differ dramatically, with median survival being 82 months [4] versus 30 months [5] for types I and II, respectively. This difference is despite the initial sensitivity of type II tumours to standard carboplatin and paclitaxel chemotherapy. However, a recent study performed by Panici and colleagues suggests the survival between the two groups to be far closer (72 vs. 62 months for types I and II, respectively [6] ), indicating that there is still much we do not understand about this disease. Adding to this argument is the finding that clear cell ovarian cancer (CCOC) is genetically separate to other forms of ovarian cancer, with different common mutations [7] and de novo chemoresistance.
Ongoing molecular characterisation and genetic studies suggests that this model may be overly simplistic, with a number of subtypes being reclassified or further divided into additional subgroups [7] [8] [9] [10] . These new subtypes demonstrate different genetic lesions and transcriptional profiles, chemosensitivity, and survival rates, indicating a need to incorporate this information into treatment plans for ovarian cancer.
Current Treatment of Patients with EOC
Currently, most women diagnosed with ovarian cancer, regardless of subtype or type, undergo total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), and omentectomy surgery to remove the ovaries, fallopian tubes, uterus, and omentum. In cases of advanced ovarian cancer, debulking of all other visible tumour deposits is also performed with the aim of achieving complete macroscopic clearance of disease. Patients are usually treated with a cytotoxic chemotherapy post-surgery, invariably a platinumbased regimen. For women with advanced disease (stage 3C/ 4) at presentation, initial treatment with chemotherapy can be undertaken prior to surgery, which can reduce surgical morbibity but does not improve overall survival [11] . Despite this invasive surgery and treatment, the majority of women recur within 2 years [12] .
In recent years, as a better understanding of the molecular landscape of EOC has become available, a number of targeted therapies have been proposed and trialled.
HGF/cMET in the Ovary
A pathway attracting attention as a potential target in ovarian cancer is the HGF/cMET axis. cMET is a receptor tyrosine kinase, typically expressed on epithelial cells, and is present in both embryonic and adult ovarian tissue [13, 14] . HGF (hepatocyte growth factor), the only known ligand for cMET, is expressed on cells of mesenchymal origin and acts as an epithelial cell mitogen, motogen, and morphogen. During ovarian development, HGF is produced by mesenchyme within the urogenital ridge adjacent to cMET-expressing epithelial cells, suggesting an involvement of this pathway in ovarian development and proliferation [15] . Paracrine signalling between the ligand and receptor has also been demonstrated during the development of the ovary and follicles [16] [17] [18] [19] . In the adult ovary, the ovarian surface epithelium and granulosa cells express cMET, while the stroma and theca cells produce HGF [20] . HGF expression is also regulated by a number of ovarian hormones [18, 21] , indicating a role for this signalling axis in oocyte maturation.
HGF/cMET in Ovarian Cancer
In recent years, misregulation of the HGF/cMET pathway has been investigated in ovarian cancer, and high expression of cMET has been identified in subsets of all four major histotypes of EOC (high-grade serous, clear cell, mucinous, and endometrioid [22] [23] [24] [25] [26] [27] [28] [29] ). However, it must be noted that the outcome from this overexpression remains unclear. While several studies have demonstrated a correlation between high cMET expression and poor prognosis [25, 30] , others have shown no statistically significant correlation between cMET expression and shorter survival [26, 29] , and still others suggest that cMET is expressed in early tumours and is associated with good prognostic factors [23] . It should be noted that the majority of these studies were performed on relatively small numbers of samples, and usually contained mixed subtypes of EOC, thus further confusing the matter. These findings are summarised in Table 1 .
High levels of the cMET ligand, HGF, in serum in women presenting with a pelvic mass is indicative of ovarian cancer ([2 standard deviations above serum levels in women with benign ovarian tumours), and is predictive of poor prognosis in women with advanced EOC [31] . HGF is also present at high levels in the ascites of patients with ovarian cancer [32, 33] , and is proposed to induce ovarian carcinoma cell migration and metastasis. Similarly, high expression of HGF in tumour cells has been correlated to decreased progression-free survival and higher serum CA-125 and CA19-9 levels [34] . While HGF is typically Targeting HGF/cMET in Ovarian Cancerexpressed in the stroma, in ovarian cancer samples it appears to be expressed in the epithelial cells [19, 29, 32, 35] , potentially generating an autocrine loop. However, it has been previously noted that HGF can regulate its own expression [36] as well as that of cMET [37] , setting in place an auto-amplification loop, and it is possible that one of the early steps of ovarian carcinogenesis is the coexpression of HGF and cMET in ovarian surface epithelium. This is supported by evidence showing that cultures of ovarian surface epithelium from women with a family history of ovarian cancer express both HGF and cMET, whereas similar cultures from women with no family history do not [38] , although how this pertains to the fallopian tube origin of ovarian cancer is yet to be ascertained. This autocrine loop is most likely then perpetuated by the high expression of HGF within the ascites fluid [32, 33] . HGF present in ascites also impacts the mesothelial cells of the peritoneum, inducing a mesothelial-to-mesenchymal transition (MMT), which may provide a more favourable environment for ovarian cancer cells to colonise and invade [34] . Kenny et al. demonstrated that ovarian cancer cells preferentially adhered to omental fibroblasts rather than mesothelial cells [39] , which may explain the increased adhesion in the presence of HGF, where MMT has been induced and HGF enhances the adhesion of ovarian cancer cells to mouse peritoneum [40] . Interestingly, use of an HGF-neutralising antibody in a mouse model of ovarian peritoneal metastasis resulted in decreased tumour cell dissemination and ascites formation [34] , adding further weight to the logic in targeting the HGF/cMET axis in ovarian cancer. Data are currently accumulating that CCOC in particular displays a high rate of cMET expression and specific MET gene amplification [41] [42] [43] [44] . Given this subtype's poor prognosis, chemoresistance, and its genetic separation from other forms of ovarian cancer, subtype-specific treatment merits further investigation.
Misregulation Mechanisms of HGF/cMET
cMET was originally identified as an oncogene as a result of a chromosomal rearrangement that fused the translocating promoter region (Tpr) to the MET kinase domain [45] . The same rearrangement has since been identified in precursor lesions of gastric cancer, suggesting that it can predispose to the development of gastric carcinomas [46] . Unlike the majority of oncogenes, mutations within the kinase domain of cMET are not frequent, although mutations have been found outside of the kinase domain (reviewed by Maroun and Rowlands [47] ). Amplification of the MET gene, or polysomy (of chromosome 7), is detected in a number of cancer types and has been correlated with poor prognosis, high protein expression, and ligand-independent activation of cMET (reviewed by Maroun and Rowlands [47] ). As yet, there is no clinically validated method for defining MET amplification, and thus the actual rate of amplification in tumour samples varies significantly between studies. The correlation between sensitivity to cMET-inhibitory agents and MET amplification remains unclear, with various studies reporting correlation [48] [49] [50] [51] , transient sensitivity [52] , or no correlation [53] [54] [55] , and as such it will be important to define a method by which copy number can be accurately determined and clinically validated. In high-grade serous ovarian cancer, The Cancer Genome Atlas (TCGA) cBioPortal [56, 57] reveals mutations in the MET gene are present in 1.3 % of cases, and amplifications are present in 1.6 % of cases; however, neither mutation nor amplification was associated with survival. High cMET expression has also been noted in the absence of mutation or amplification, most likely a result of transcriptional upregulation. A number of factors are known to result in increases in cMET expression, including hypoxia [58] , and activation of other oncogenes, such as Ras and Ret [59] . HGF is rarely found to be mutated or amplified in cancer, and a search of the TCGA cBioPortal [56, 57] revealed that HGF was mutated in 0.6 % of high-grade serous ovarian cancer patients (with mutations resulting in truncation), and amplified in 1.3 % of cases. Although an association between the rs1800793 single nucleotide polymorphism and ovarian cancer mortality has been identified, this did not correlate with changes in protein or messenger RNA (mRNA) expression [29] . However, transcriptional upregulation has been observed resulting from Stat-3 and c-Src expression [60] , and the coexpression of HGF and cMET in tumour cells can drive autocrine activation, as well as increased transcription for both genes. A number of studies have identified that HGF expression and autocrine cMET activation decreases sensitivity to cMET inhibitors, and stromal HGF levels have been linked to clinical responses in patients treated with the anti-HGF agent ficlatuzumab [61] [62] [63] , demonstrating the importance of the use of biomarkers in predicting clinical responses.
In the absence of ligand, cMET can also be activated by integrin interaction, the hyaluronan receptor CD44, plexins, and interaction with other receptor tyrosine kinases such as EGFR, RET, and Ron kinase, as well as some G-protein-coupled receptors [64] [65] [66] [67] [68] , indicating that it may be necessary to use cMET inhibitors in combination with other agents.
Therapeutic Agents Against HGF/cMET
A number of therapeutic agents targeting HGF or cMET have been evaluated in preclinical cancer models or clinical trials for various solid cancers in recent years, with varying levels of success. Broadly, these agents fall into two categories: antibodies targeting HGF or cMET, the majority of which prevent ligand-receptor interaction; or small molecule inhibitors, typically designed to block phosphorylation of cMET and thus prevent downstream signalling. Gene therapy using adenoviruses expressing HGF-antagonist intra-molecules is also under investigation in patients [69] . Details of agents recently in clinical trials are detailed in Table 2 . It has become apparent in recent years that single-targeted drug therapy is usually ineffective and frequently results in resistance. As such, it may ultimately be necessary to combine anti-HGF/cMET therapeutics with additional agents, such as those targeting the EGFR, PI3K/Akt/mTOR, or MEK/ERK pathways; however, the efficacy and target population of anti-HGF/cMET agents must first be defined.
Clinical trials were traditionally designed to test agents that were assumed to have the same effect on all individuals, most recently cytotoxic chemotherapeutics targeting generic disease mechanisms. Such trials are most efficacious when they assess a potential therapeutic effect that is about the same size or slightly smaller than the effect of the natural variation that exists between individuals [70] . One of the surprising details to come out of recent trials using HGF-or cMET-targeting agents is the absence of patient selection using biomarkers, or indeed correlation of results post hoc, with HGF/cMET expression.
HGF/cMET Therapeutics in Ovarian Cancer
While few of the phase I trials have included patients with ovarian cancer (see Table 3 and Sect. 6), these have been sufficiently promising to merit a phase II trial using rilotumumab in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (NCT01039207) [71] . However, using primary endpoints of tumour response and 6-month progression-free survival, and secondary endpoints of progression-free survival and overall survival, this study concluded that although rilotumumab was well tolerated, it had limited activity and would not be investigated further as a single agent. The authors of the study concluded that the use of predictive biomarkers might guide a more targeted approach to treatment in the future, highlighting a recurring theme in the use of both cMET-and HGF-targeted agents.
Biomarkers for the HGF/cMET Pathway
Although a number of studies have attempted to define biomarkers for overactivation of the cMET pathway, no clinically validated tests are currently available. Immunohistochemical staining for cMET and phosphorylated cMET, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for MET and HGF, and gene amplification of MET, have all been reported in the literature as potential biomarkers for selection of patients who may benefit from HGF/cMET-targeting agents. However, the variation in reported incidences of overexpression/amplification within similar cohorts of patients confirm the need for carefully validated assays.
Immunohistochemistry for cMET
Estimates of the frequency of HGF/cMET dysregulation differs between tumour types, but even within individual tumour types there exists a wide variation in the reported frequency. For example, recent immunohistochemistry (IHC) studies performed on gastric tumour samples have reported cMET overexpression in 4-63 % of cases [72- 77], and various studies performed in ovarian cancer estimate high expression of cMET to be present in 11-68 % of cases [22, 23, 25, 26, 30] (Table 1 ). The majority of the estimates above come from IHC studies, using a number of different antibodies, but no consensus on scoring criteria yet exists, nor whether cytoplasmic or membranous staining for cMET is important. Work performed by Koeppen and colleagues has described the validation of the CON-FIRM anti-total cMET (SP44) rabbit monoclonal antibody on formalin-fixed paraffin-embedded tissue as part of the phase II trial testing onartuzumab in non-small cell lung cancer (NSCLC) [78] . Using cell lines with known levels of cMET expression, comparisons between SP44 antibody staining, flow cytometry (using a different anti-Met antibody), and mRNA levels, it was determined that the SP44 antibody specifically recognises cMET, and not the closely-related Ron receptor. Furthermore, a comprehensive clinical scoring system was determined, which enabled a cut-off of 50 % (of cells stained moderate/strong) to be utilised in the trial to differentiate patient outcomes when treated with onartuzumab [78] . A number of additional antibodies (D1C2 and A2H2-3) have also shown promise for use in clinical studies for detection of cMET levels; however, additional validation on larger cohorts of clinically annotated samples will be required prior to their incorporation into clinical practice (Koeppen et al. [102] and Gruver et al. [79] ).
Gene Amplification and Copy Number of Met
Other studies have used gene amplification or gene copy number to determine if MET has been amplified (either the gene itself or larger portions of chromosome 7) [73, 78, 80, 81] , although the usefulness of MET genetic amplification as a biomarker, and its correlation to drug sensitivity, has yet to be validated in large-scale trials. Similarly, the correlation between copy number, protein expression level, and responsiveness to cMET inhibitory agents is still under investigation [78] .
Phosphorylated cMET
In a number of cancer types, including ovarian, amplification and mutation of cMET are relatively rare, making expression or activation (phosphorylation) a better readout of activity of the receptor. Although a number of studies have incorporated staining for phosphorylated cMET, it is rare that samples both pre-and post-treatment are available, and it is not yet clear that a reduction in IHC signal with treatment correlates to a therapeutic response in the patient. Eder et al. and Yap and colleagues both showed decreases in phosphorylated c-Met in tumour samples after treatment, although the best patient responses identified were stable disease [82, 83] . Adding to the complexity of this matter is the labile nature of the phospho group (and indeed many other post-translational modifications), and its preservation in formalin-fixed paraffin-embedded tissue. A number of studies have demonstrated that proteins are rapidly dephosphorylated upon oxygen deprivation, with the majority of phosphoproteins being lost if not fixed within 60 min [84, 85] . Additionally, it is proposed that the stability of different phospho-epitopes vary, both within a single tumour type and between tissue types [86] , making scoring and/or quantification of phospho-antibody signals inherently difficult. All of these factors decrease the reliability of phospho-cMET as a reliable biomarker for overactivation of the pathway, making selection of patients for anti-HGF/cMET-targeted therapies more difficult. It should be noted that these difficulties are not unique to the HGF/cMET pathway but are applicable to increasing numbers of therapeutics that target pathways upregulated in cancer cells, many of which are defined by phosphoactivation rather than intrinsic genetic lesions.
Circulating HGF
While circulating HGF has been reported as elevated in patients with cancer in a number of studies, its use as a biomarker is still under investigation. Both onartuzumab and ficlatuzumab, therapeutic antibodies directed against HGF, stabilise the protein and cause increases in the serum with treatment [61, 87, 88] . This enables circulating HGF to be used as a pharmacodynamic marker for these agents, but perhaps not as a catch-all predictive biomarker for selecting patients for HGF/cMET therapies. Furthermore, elevated HGF levels are observed in a number of disease settings, including virus/bacterial infections, graft-versus-host disease, and following surgical procedures, making their use as a biomarker for selection of patients less favourable [89] [90] [91] . It is also yet to be vigorously validated how circulating HGF levels relate to HGF levels within the tumour micro-environment [92] . Because HGF is a secreted, soluble factor, it must be noted that HGF within the tumour tissue may not have been generated locally.
A Requirement for Biomarkers
Confusing the biomarker discussion is the finding that two patients with alveolar soft tissue sarcoma, whose archival tumour tissue was negative for c-Met IHC and who have been treated with tivantinib (a cMET inhibitor) for [3 years, have maintained stable disease for that period [93] . This may indicate that additional biomarkers need to be identified, or that fresh tumour biopsies need to be acquired prior to treatment commencement, in order to assess the cMET status more accurately, or that cMETindependent actions of tivantinib are involved [94] . Recently, the need for biomarkers when targeting the HGF/cMET pathway has become apparent, with the finding that patients with NSCLC with low cMET expression deteriorate when receiving onartuzumab (a monoclonal antibody targeting Met) ? erlotinib than erlotinib ? placebo [95] . Spigel and colleagues proposed that dual inhibition of EGFR (by erlotinib) and cMET might have different consequences in tumours with lower versus higher cMET expression, such that this effect may only be seen on a background of EGFR inhibition. However, a similar finding was reported in a study utilising rilotumumab (AMG 102, an anti-HGF monoclonal antibody) in metastatic gastric or esophagogastric junction cancer (Oliner et al. [103] ). However, it should be noted that the final study report for this trial [96] showed no difference in progression-free survival or overall survival between cMET-low patients receiving rilotumumab ? chemotherapy, or chemotherapy alone.
What is becoming quite apparent is that not everyone may benefit from receiving targeted therapies such as those against HGF/cMET and, dismayingly, some receiving the therapy may in fact do worse than those receiving placebo. This makes it imperative to determine the population who will benefit, and thus to incorporate appropriate biomarkers into all studies moving forward. For ovarian cancer, which is typically diagnosed late, and where the opportunity for second-line treatment is limited, it is vital that only patients who will potentially benefit from an agent receive it.
HGF/cMET Inhibitor Trials in Ovarian Cancer
As described above, the only study with results available addressing the use of agents targeting HGF/cMET in ovarian cancer is that in which patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer were treated with rilotumumab (NCT01039207) [71] . This trial was stopped in the first phase of recruitment due to a lack of sufficient positive results to progress to the second phase of the trial. Of the 31 patients treated, one achieved a complete response and six experienced stable disease (all patients had previously received platinum-based therapy). However, surprisingly, no biomarkers were used, nor were analyses performed post hoc on patients responding to treatment. With current estimates of high cMET expression occurring in 11-68 % of ovarian cancer cases (see Table 1 ) [22, 23, 25, 26, 30] , it is possible that as few as three patients enrolled within the study were in a position to benefit from receiving the anti-HGF antibody, and that as many as 29 patients potentially deteriorate upon receiving the therapy.
Interestingly, a number of phase I trials of HGF/cMETtargeting agents have included patients with ovarian cancer [54, 61, 82, 88, 97, 98] , several of which have reported favourable responses, with some correlated to biomarkers. Preliminary data presented by Buckanovich and colleagues [104] described a phase II discontinuation trial that had been halted due to high clinical activity seen in women with ovarian cancer treated with cabozantinib (a dual cMET and VEGFR2 inhibitor), although these data are yet to be published. However, trials with cabozantinib directed at women with recurrent, progressive, or persistent, epithelial ovarian, fallopian tube, or peritoneal cancer are ongoing (NCT02315430 and NCT01716715).
Biomarker-Based Clinical Trials
With relatively small numbers of individuals likely to benefit from targeted therapies, such as those against the HGF/cMET pathway, it may prove more efficacious to utilise biomarker-based trials (rather than trials based on the primary site of a tumour), such as the recent National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial in which more than 200 actionable mutations/amplifications/translocations were assessed, and patients were matched to investigational drugs directed to the lesion of interest that their tumour harboured. Although randomised clinical trials remain the gold standard for assessing the efficacy of new agents, their design is not feasible/optimal time-or expense-wise for patients with rapidly advancing malignancies, or for agents designed against mutations present in a small proportion of the population.
Conclusions and Recommendations
There is an urgent need to identify new therapeutics for patients with ovarian cancer and the HGF/cMET signalling pathway merits further investigation. However, there are a number of factors that need to be addressed in order to assess the utility and efficacy of such therapeutics. First and foremost is the requirement for good biomarker/s that can be used clinically, such that the true percentage of patients with each subtype of EOC exhibiting high HGF or cMET activity can be assessed. This will require the use of large sample sizes, and agreement as to how to score such samples. However, in recent years, IHC assays to determine HER2 status in various cancers have been successfully implemented clinically, and are now used as determinants for treatments in breast and gastric cancer. It seems likely that IHC will be used as amplifications and mutations are relatively rare and, to date, little correlation has been seen between amplification, protein expression, and sensitivity to inhibitors. Using a validated system to measure cMET will also enable retrospective analyses as to the prognostic value of expression. Of grave importance is determining the consequences of treating individuals with low cMET expression with cMET inhibitors and, again, this will require the incorporation of biomarkers into ongoing trials and should be a requirement for enrolment in the first instance.
Small molecule inhibitors and therapeutic antibodies have the potential to change treatment options and survival rates in many cancers. However, these agents are designed to target particular genetic lesions or specific aberrations in signalling pathways, and thus it is logical, and likely to only be of benefit to, individuals harbouring the lesions/ signalling aberrations against which the agents are designed. In order to accomplish this, it is imperative that we utilise biomarkers to both identify such patients and to be able to determine the usefulness of such agents in these patients.
